NHS Grampian

Formulary Group work programme

The decisions of the Formulary Group meeting (Tuesday 15 April 2025) will be published by 30 April 2025.

Publication schedule

This information is updated monthly.

Formulary Group work programme

The Group meets monthly on the third Tuesday of each month (excluding July and December). The following list includes medicines that will be scheduled for review in the next three to four months. It is indicative and may be subject to change.

Medicine and indication	Meeting date
bimekizumab 160mg solution for injection in pre-filled syringe, pre-filled pen (Bimzelx®)	
SMC 2410	
Indication: for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. For patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	May 2025
cemiplimab 350mg concentrate for solution for infusion (Libtayo®)	
SMC 2719	
Indication: as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.	TBC
dabrafenib 10mg dispersible tablets (Finlee®)	
SMC 2667	
Indication: in combination with trametinib (Spexotras®) for: - the treatment of paediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. - the treatment of paediatric patients aged 1 year and older with high-grade glioma with a BRAF V600E mutation who have received at least one prior radiation and / or chemotherapy treatment.	Apr 2025
deucravacitinib 6mg film-coated tablets (Sotyktu®)	
SMC 2581	
Indication: for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	May 2025

Medicine and indication	Meeting date
elafibranor 80mg film-coated tablets (Iqirvo®)	
SMC 2714	
Indication: for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.	TBC
elranatamab 40mg/mL solution for injection (Elrexfio®)	
SMC 2669	
Indication: as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	May 2025
etrasimod 2mg film-coated tablets (Velsipity®)	
SMC 2655	
Indication: for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.	TBC
Lonsurf® 15mg/6.14mg, 20mg/8.19mg film-coated tablets (trifluridine/tipiracil)	
SMC 2654	
Indication: in combination with bevacizumab for the treatment of adults with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.	Apr 2025
Methoxyflurane (Penthrox®) 99.9%, 3mL inhalation vapour, liquid	
FG1 473/25	
Indication: [off-label] for patients having surgical abortion or evacuation retained products of conception after abortion with local anaesthetic in theatre at ARI.	Apr 2025
relugolix 120mg film-coated tablets (Orgovyx®)	
SMC 2678	
Indications: - for the treatment of adult patients with advanced hormone-sensitive prostate cancer - for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.	TBC

Medicine and indication	Meeting date
risankizumab 180mg, 360mg solution for injection in cartridge, 600mg concentrate for solution for infusion (Skyrizi®)	
SMC 2686	
Indication: for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.	TBC
somapacitan 5mg/1.5mL, 10mg/1.5mL 15mg/1.5mL solution for injection in pre-filled pen (Sogroya®)	
SMC 2629	
Indication: for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD). SMC restriction: for children aged 3 years and above and adolescents with growth failure due to growth hormone deficiency (paediatric GHD).	TBC
teclistamab 10mg/mL, 90mg/mL solution for injection (Tecvayli®)	
SMC 2668	
Indication: as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	May 2025
ublituximab 150mg concentrate for solution for infusion (Briumvi®)	
SMC 2731	
Indication: treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. SMC restriction: treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.	TBC
vamorolone 40mg/mL oral suspension (Agamree®)	
SMC 2721	
Indication: treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.	TBC
zanubrutinib 80mg hard capsules (Brukinsa®)	
SMC 2684	
Indication: as monotherapy for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.	Apr 2025

END